MA46286A - Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1 - Google Patents

Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1

Info

Publication number
MA46286A
MA46286A MA046286A MA46286A MA46286A MA 46286 A MA46286 A MA 46286A MA 046286 A MA046286 A MA 046286A MA 46286 A MA46286 A MA 46286A MA 46286 A MA46286 A MA 46286A
Authority
MA
Morocco
Prior art keywords
glp
receptor agonist
pyrazolopyridine derivative
pyrazolopyridine
derivative
Prior art date
Application number
MA046286A
Other languages
English (en)
Inventor
Masahide Aoki
Yoshiyuki Furuta
Nobuyuki Hori
Takuma Kamon
Hirotaka Kashiwagi
Takahiro Kawai
Atsushi Matsuo
Masahiro Nishimoto
Yoshikazu Nishimura
Hiroko Ogawa
Kyoko Oguri
Tsutomu Sato
Takuya Shiraishi
Satoshi Tanida
Satoshi Tsuchiya
Shoshin Yoshida
Hitoshi Yoshino
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA46286A publication Critical patent/MA46286A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA046286A 2016-09-26 2017-09-26 Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1 MA46286A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016187605 2016-09-26

Publications (1)

Publication Number Publication Date
MA46286A true MA46286A (fr) 2019-07-31

Family

ID=61689595

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046286A MA46286A (fr) 2016-09-26 2017-09-26 Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1

Country Status (37)

Country Link
US (5) US10858356B2 (fr)
EP (3) EP4349840A3 (fr)
JP (4) JP6567778B2 (fr)
KR (1) KR102223227B1 (fr)
CN (1) CN109790161B (fr)
AU (4) AU2017330733B2 (fr)
BR (1) BR112019005322A2 (fr)
CA (1) CA3038479C (fr)
CL (1) CL2019000663A1 (fr)
CO (1) CO2019002595A2 (fr)
CR (1) CR20190149A (fr)
DK (1) DK3517538T3 (fr)
DO (1) DOP2019000074A (fr)
EA (2) EA037989B1 (fr)
EC (1) ECSP19020228A (fr)
FI (1) FI3517538T3 (fr)
HR (1) HRP20240499T1 (fr)
HU (1) HUE066583T2 (fr)
IL (2) IL264945B (fr)
JO (1) JOP20190060A1 (fr)
LT (1) LT3517538T (fr)
MA (1) MA46286A (fr)
MD (1) MD3517538T2 (fr)
MX (2) MX2019003488A (fr)
PE (1) PE20190709A1 (fr)
PH (1) PH12019500659A1 (fr)
PL (1) PL3517538T3 (fr)
PT (1) PT3517538T (fr)
RS (1) RS65398B1 (fr)
SA (1) SA519401409B1 (fr)
SG (1) SG11201901565VA (fr)
SI (1) SI3517538T1 (fr)
TN (1) TN2019000054A1 (fr)
TW (1) TWI753946B (fr)
UA (1) UA125586C2 (fr)
WO (1) WO2018056453A1 (fr)
ZA (1) ZA201901070B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
SG11202003746UA (en) * 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
TWI707683B (zh) * 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
JP7360301B2 (ja) 2019-11-08 2023-10-12 Ｋｙｂ株式会社 作動流体供給システム
KR20220156535A (ko) * 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021249492A1 (fr) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 Composé de benzobisoxazole à substitution méthyle et son utilisation
IL299704A (en) * 2020-07-20 2023-03-01 Eccogene Shanghai Co Ltd Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them
CN116323599A (zh) * 2020-08-06 2023-06-23 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4204415A1 (fr) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN115884969A (zh) 2020-09-01 2023-03-31 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
US20230322771A1 (en) * 2020-09-07 2023-10-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
CA3200245A1 (fr) 2020-11-27 2022-06-02 Junjun Wu Derive de benzimidazole, son procede de preparation et son utilisation medicale
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (fr) 2021-03-24 2022-09-29 塩野義製薬株式会社 Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
AU2022300055A1 (en) 2021-06-24 2024-01-18 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and composition and use thereof
WO2023016546A1 (fr) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Agonistes de glp-1 hétérocycliques
WO2023038039A1 (fr) 2021-09-08 2023-03-16 塩野義製薬株式会社 Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité
WO2023138684A1 (fr) * 2022-01-24 2023-07-27 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
WO2023151574A1 (fr) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Agonistes hétérocycliques de glp-1
WO2023220109A1 (fr) 2022-05-11 2023-11-16 Eli Lilly And Company Compositions pharmaceutiques à base de glp1
WO2023220112A1 (fr) 2022-05-11 2023-11-16 Eli Lilly And Company Compositions de comprimé glp1
CN116003403B (zh) * 2022-11-20 2024-07-23 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
WO2024113004A1 (fr) * 2022-11-28 2024-06-06 The University Of Melbourne Combinaisons pharmaceutiques et leurs utilisations
WO2024129676A1 (fr) * 2022-12-13 2024-06-20 Eli Lilly And Company Régime posologique d'orforglipron pour traiter un sujet atteint de diabète de type 2 (t2d), d'obésité ou de surpoids avec au moins une comorbidité liée au poids
WO2024137426A1 (fr) 2022-12-19 2024-06-27 Eli Lilly And Company Procédé de production de glp1 ra et d'intermédiaires correspondants
WO2024153070A1 (fr) * 2023-01-17 2024-07-25 Fochon Biosciences, Ltd. Agonistes de glp-1 r et leurs utilisations
WO2024169952A1 (fr) * 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998438A (en) 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
WO1999050262A1 (fr) 1998-04-01 1999-10-07 Janssen Pharmaceutica N.V. Derives de pyridine inhibiteurs de pde iv
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
CN1771231B (zh) * 2002-08-26 2011-05-25 武田药品工业株式会社 钙受体调节性化合物及其用途
DE10360774A1 (de) 2003-12-23 2005-07-28 Robert Bosch Gmbh Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil
WO2006048727A1 (fr) 2004-11-02 2006-05-11 Pfizer Products Inc. Ligands de latame/amine piperazinylphenalkyle pour le recepteur 5ht1b
EA018036B1 (ru) * 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
CN101959405B (zh) 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
RS54560B1 (en) 2008-06-10 2016-06-30 Abbvie Inc. TRICYCLIC UNITS
JP5755217B2 (ja) * 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011004882A1 (fr) * 2009-07-09 2011-01-13 ラクオリア創薬株式会社 Antagoniste de la pompe à acide destiné au traitement de maladies associées à un transit gastro-intestinal anormal
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
CA2858571C (fr) * 2011-12-08 2021-03-16 Research Triangle Institute Composition et methode pour des antagonistes des recepteurs de neuropeptide (npsr)
WO2014122067A1 (fr) * 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh Nouveaux acides indanyloxydihydrobenzofuranylacétiques
CN103086955B (zh) 2013-02-19 2014-10-15 中国医学科学院医药生物技术研究所 3-氨基-4-烷氧亚胺基哌啶的制备方法
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
EP2993174A1 (fr) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Dérivés de pyrazolopyridine et leur utilisation en thérapie
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Also Published As

Publication number Publication date
US20240262824A1 (en) 2024-08-08
EP3517538A4 (fr) 2020-06-10
DK3517538T3 (da) 2024-03-25
HRP20240499T1 (hr) 2024-07-05
FI3517538T3 (fi) 2024-05-20
US20240246971A1 (en) 2024-07-25
CR20190149A (es) 2019-08-27
CA3038479A1 (fr) 2018-03-29
EP3517538B1 (fr) 2024-03-13
PL3517538T3 (pl) 2024-06-10
AU2020223687B2 (en) 2022-04-14
TWI753946B (zh) 2022-02-01
HUE066583T2 (hu) 2024-08-28
AU2022205222A1 (en) 2022-08-04
IL264945A (en) 2019-05-30
UA125586C2 (uk) 2022-04-27
EA037989B1 (ru) 2021-06-21
US10858356B2 (en) 2020-12-08
PT3517538T (pt) 2024-04-09
JP7280929B2 (ja) 2023-05-24
JP6957564B2 (ja) 2021-11-02
WO2018056453A1 (fr) 2018-03-29
PE20190709A1 (es) 2019-05-17
DOP2019000074A (es) 2019-05-31
MD3517538T2 (ro) 2024-09-30
SA519401409B1 (ar) 2022-04-07
JP2019203015A (ja) 2019-11-28
RS65398B1 (sr) 2024-04-30
JOP20190060A1 (ar) 2019-03-26
AU2024201884A1 (en) 2024-04-11
LT3517538T (lt) 2024-05-10
CO2019002595A2 (es) 2019-03-29
AU2022205222B2 (en) 2024-04-04
TN2019000054A1 (en) 2020-07-15
EA202190802A2 (ru) 2021-07-30
EA202190802A3 (ru) 2021-10-29
US20190225604A1 (en) 2019-07-25
JP6567778B2 (ja) 2019-08-28
JP2022003087A (ja) 2022-01-11
EA201990518A1 (ru) 2019-12-30
US20230382912A1 (en) 2023-11-30
EP4134367A1 (fr) 2023-02-15
EP4349840A2 (fr) 2024-04-10
CN109790161A (zh) 2019-05-21
AU2020223687A1 (en) 2020-09-10
JPWO2018056453A1 (ja) 2019-07-11
SG11201901565VA (en) 2019-03-28
JP2023100963A (ja) 2023-07-19
CN109790161B (zh) 2022-03-11
IL264945B (en) 2021-10-31
MX2019003488A (es) 2019-12-16
BR112019005322A2 (pt) 2019-07-02
AU2017330733A1 (en) 2019-03-14
US20210017176A1 (en) 2021-01-21
ECSP19020228A (es) 2019-06-30
MX2022004071A (es) 2022-05-03
EP4349840A3 (fr) 2024-07-10
US11814381B2 (en) 2023-11-14
CL2019000663A1 (es) 2019-07-26
NZ751725A (en) 2021-03-26
TW201827426A (zh) 2018-08-01
SI3517538T1 (sl) 2024-05-31
EP3517538A1 (fr) 2019-07-31
ZA201901070B (en) 2021-06-30
PH12019500659A1 (en) 2019-12-16
CA3038479C (fr) 2021-06-22
KR20190039591A (ko) 2019-04-12
AU2017330733B2 (en) 2020-05-28
IL287166A (en) 2021-12-01
KR102223227B1 (ko) 2021-03-08

Similar Documents

Publication Publication Date Title
MA46286A (fr) Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1
ZA201802371B (en) Glucagon receptor agonists
MA45069A (fr) Protéines agonistes du récepteur trail monocaténaires
FR3021386B1 (fr) Raccord tubulaire a connexion automatique
BR112016021466A2 (pt) Definições de nível para codecs de vídeo de múltiplas camadas
ZA201702494B (en) High strength small diameter fishing line
IL251412B (en) Hollow probe with sleeve
GB2551945B (en) Novel GLP-1 receptor agonist peptides
BR112016027096A2 (pt) compostos de receptores-alvo de serotonina e métodos
HK1231414A1 (zh) 胃輕癱用 受體激動劑
DK3349631T3 (da) Toiletsæde med en automatisk renseindretning
TH1601000316A (th) อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
ES1156661Y (es) Dispositivo para el fregado de la espalda
IL245835A0 (en) A device with an expanding cleaning head
HUE047148T2 (hu) MET receptor antagonista proteinek
DK2984924T3 (da) Svingmekanisme
FR3016496B1 (fr) Gaine tubulaire